Dr Hohenhaus has had a distinguished career in Veterinary medicine. She is a Diplomate, American College of Veterinary Internal Medicine (Oncology), a Diplomate, American College of Veterinary Internal Medicine  (Small Animal Internal Medicine), and a DVM from Cornell University. She is a Certified Veterinary Journalist, a recipient of the New York City Veterinary Medical Association Outstanding Service to Veterinary Medicine Award, recipient of the DeBakey Award for Excellence, and a listed author on 39 publications in PubMed in the disciplines of oncology, internal medicine, and transfusion medicine, including: squamous cell carcinoma, mast cell tumors, melanoma, exocrine pancreatic insufficiency, and anemia. She has authored 19 veterinary textbook chapters, and is currently investigating immunotherapy for hemangiosarcoma in dogs. Dr. Hohenhaus lectures nationally and internationally, most recently in the Kuala Lumpur, Malaysia and Capetown, South Africa.

Dr Impellizeri, with a Veterinary career spanning over 25 years, has held many distinguished positions, and has received many honors and awards. He is a Diplomate, American College of Veterinary Internal Medicine (Oncology), a Member, Royal College of Veterinary Surgeons, a Visiting Scholar, Biology, at Vassar College, Director, Barrymore  Center for Advanced Cancer Therapeutics focusing on Cancer Immunotherapy, Electrochemotherapy, and Electrogenetransfer, and Director- Bone Marrow Transplant Una —Veterinary Specialty Center of the Hudson Valley. He has been involved in groundbreaking research with recent credits including the first DNA vaccine in animals against SARS-2 - Safety and immunogenicity of Vet-COVID-eVAX, an anti-SARS-00V-2 plasmid DNA vaccine in cats, the first Treatment with Photodynamic Therapy for Canine Gliomas, the first Treatment with Reversible Electrochemotherapy for Canine Brain Cancer, the first Treatment of Green Sea Turtle (Chelonia mydas) in the United States for Fibropapilloma with Electrochemotherapy in conjunction with the University of Florida, College of Veterinary Medicine and The Turtle Hospital, Marathon, Florida, and the first Treatment of an Asian Elephant (Elephas maximus) with mammary cancer with Electrochemotherapy, El Paso Zoo, El Paso, Texas. He is an invited speaker both nationally and internationally for many years, and has over 24 publications to his credit.

Dr. Goddard, with over 46 years in medicine, is Clinical Professor of Medicine at NYU School of Medicine. He received his medical degree from the Royal London Hospital Medical College, and has received various awards and held a variety of positions over his extensive and distinguished career. They include a research fellowship at the Arthritis and Rheumatism Council of the United Kingdom, researcher at Professor John Holborow’s laboratory studying neutrophil function in rheumatoid arthritis, a  Doctorate in Medicine from the University of London, a Fellowship in rheumatology at Charing Cross and Westminster Hospitals in London, positions at Albert Einstein Medical Center and Temple University, Philadelphia where he directed the rheumatic diseases research laboratories, Associate Chief of Rheumatology at Winthrop University Hospital, Chief of Rheumatology at Long Island College Hospital, and Professor of Clinical Medicine at SUNY HSC. He has served as member of the VA immunology Section as well as ad hoc review for rheumatologic publications.  He currently serves as Medical Director for NYU Ambulatory Care at Brooklyn Heights and Cobble Hill, Brooklyn, New York.  He serves as a member of the NYU Institutional Review Board.  He continues his activities in clinical research serving as PI for clinical trials in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout, and systemic lupus erythematosus.  He is a Fellow of the American College of Physicians.

Dr Allan has spent the last decade specializing in Lymphoma, conducting research into CLL and Richter’s Syndrome as well as Lymphoma, and is an invited speaker nationally and internationally in these areas. He is an Assistant Professor in Hematology and Oncology, a Fellow, Weill Cornell Medical College, and has received many honors and awards. He is a Member of the CLL Rearch Center, has more than 38 research publications to his credit, and has over 20 peer reviewed extracts. His current research activities are extensive and include Potential Genetic and Transcriptomic Mechanisms of Resistance to BTK Inhibition in CLL,  and Mechanisms of enhancer regulation in leukemia. Published research includes:  A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma, Targeting CD38 with daratumumab lethal to Waldenström macroglobulinaemia cells, Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22, and CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.  Leukemia and Lymphoma, Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N.

Dr Abraham Chachoua, with over 30 years in medicine, holds several distinguished positions including  Professor of Oncology, Department of Medicine at NYU Grossman School of Medicine, and Professor, Department of Urology at NYU Grossman School of Medicine. He specializes in the treatment of advanced Thoracic cancer, continues to focus on the treatment of cancers of the lung and chest, and is currently conducting important immunology research. He has a Fellowship at Alfred Hospital in Hematology/Oncology, is the recipient of the American Cancer Society career development award, and has over 90 publications to his credit. Most recently, they include Radiotherapy induces responses of lung cancer to CTLA-4 blockade, Toward the complete control of brain metastases using surveillance screening and stereotactic radiosurgery, and Stereotactic radiosurgery for focal leptomeningeal disease in patients with brain metastases.

Professor Halperin, an Orrington Lunt Professor, is a distinguished Physicist with a career spanning more than 45 years. He is the recipient of the prestigious international Fritz London Memorial Prize in physics awarded only once every three years and has over 50 honors and appointments. These include Chair, Department of Physics and Astronomy (NU), Director, Integrated Science Program (NU), Professor, Northwestern University, Chair, Division of Condensed Matter Physics, American Physical Society, and Chair, C5 Commission, International Union of Pure and Applied Physics. He is a life member and Fellow, American Physical Society, Fellow of the Institute of Physics (UK) and Member, Ampere Society. He has served as an adviser to the Federal Trade Commission in Chicago and Washington, and to the Department of Energy (Basic Energy Sciences). He has testified in Congress on both the Helium-3 and Helium-4 crisis, and has functioned as an external phd examiner for Helsinki University of Technology, Universite de Grenoble, Queen's University of Kingston Ontario, and Universite Josef Fourier. He has over 250 publications to his credit, and has conducted research in many areas including Quantum Liquids and Solids, Superconductivity, Quantum Size Effects in Metallic Particles, and Nuclear Magnetic Resonance. He is also a joint author in the research Evidence For Broken Time-Reversal Symmetry in a Topological Superconductor, and Alterations in Magnetic Characteristics Produced by Intracellular Particles.

Dr Yelena Novik has been a physician for over 33 years, and specializes in breast cancer. She has held and received numerous positions and awards. Dr Novik has a Fellowship at Montefiore Medical Center, Hematology & Oncology, is a Fellow at the American College of Physicians, is Chair of a specialized NYU School of Medicine’s Institutional Review Board, and is currently Associate Professor of Clinical Medicine, NYU School of Medicine. She is also certified as a FDA Clinical Investigator Training, a past Chair, Cancer Committee, Belvue Hospital, Chair, Cancer Clinical Investigation Committee, Perlmutter Cancer Center, past Medical Director, Clinical Trials, NYU Cancer Institute. and currently participates in clinical trials at Perlmutter Cancer Center. She has been and continues to be an  Institutional Principal Investigator for Therapeutic Trials in more than 25 trials and has over 30 publications and over 50 publication extracts to her credit and is currently involved in three Clinical Trials. They are Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer, Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer, and Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors.

Professor Robbins has over 25 years experience in the investment management of large portfolios ranging between $10 billion and $100 billion for major institutions all over the worlds. He is a Professor at Columbia University teaching AI in portfolio management, and is authoring a book entitled Quantitative Asset Management to be published by McGraw Hill. He is also applying AI to Cancer research in several programs including collaborations with Frederick National Laboratory for Cancer Research.He qualified as a nuclear engineer, specializing in the medical and military applications of electromagnetic radiation. He received a BS in Engineering Physics (Nuclear). He received his qualification as a Chartered Financial Analyst (CFA).